Nuvectis Pharma (NVCT) Projected to Announce Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.25) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Price Performance

Nuvectis Pharma stock opened at $21.52 on Monday. Nuvectis Pharma has a 52 week low of $5.55 and a 52 week high of $29.27. The company’s 50 day moving average price is $16.42 and its two-hundred day moving average price is $11.52. The stock has a market cap of $570.93 million, a P/E ratio of -16.43 and a beta of -0.26.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NVCT shares. HC Wainwright boosted their price objective on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a research report on Friday, June 5th. Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. UBS Group set a $33.00 price target on shares of Nuvectis Pharma in a report on Monday, July 6th. Finally, Roth Capital increased their price target on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has an average rating of “Hold” and a consensus target price of $35.00.

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri bought 50,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was acquired at an average cost of $18.32 per share, with a total value of $916,000.00. Following the completion of the transaction, the insider directly owned 3,186,576 shares of the company’s stock, valued at $58,378,072.32. This represents a 1.59% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ron Bentsur bought 12,500 shares of the stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the chief executive officer owned 3,688,424 shares of the company’s stock, valued at approximately $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 28.55% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nuvectis Pharma

Several large investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in Nuvectis Pharma by 31.3% during the fourth quarter. Barclays PLC now owns 24,185 shares of the company’s stock valued at $183,000 after purchasing an additional 5,760 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Nuvectis Pharma by 15.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock worth $332,000 after purchasing an additional 6,040 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Nuvectis Pharma by 3,398.9% in the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares during the period. Bank of America Corp DE raised its position in shares of Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at approximately $53,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.